PSNL
Personalis, Inc.
NASDAQ · USHealthcareMedical - Diagnostics & Research
$13.34-13.32%
Price as of Jul 20, 2026
PSNL financials
Personalis, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $84.6M | $73.5M | $65.0M |
| Cost of revenue | $53.9M | $57.8M | $55.3M | $51.7M |
| Gross profit | -$53.9M | $26.8M | $18.2M | $13.3M |
| Operating expenses | $34.2M | $95.1M | $128.1M | $128.9M |
| Operating income | -$88.1M | -$68.3M | -$109.9M | -$115.5M |
| Net income | -$81.3M | -$81.3M | -$108.3M | -$113.3M |
| EBITDA | -$71.0M | -$70.3M | -$96.8M | -$104.6M |
| Basic EPS | $-0.91 | $-1.37 | $-2.25 | $-2.48 |
| Diluted EPS | $-0.91 | $-1.37 | $-2.25 | $-2.48 |
| Balance sheet | ||||
| Cash & equivalents | $124.2M | $91.4M | $57.0M | $89.1M |
| Total assets | $334.2M | $270.3M | $225.1M | $292.7M |
| Total liabilities | $73.0M | $67.3M | $95.7M | $74.6M |
| Stockholders’ equity | $261.2M | $203.0M | $129.4M | $218.1M |
| Total debt | $39.9M | $44.2M | $47.7M | $48.6M |
| Net debt | -$84.3M | -$47.2M | -$9.3M | -$40.5M |
| Cash flow | ||||
| Operating cash flow | -$74.9M | -$45.1M | -$56.3M | -$70.2M |
| Capital expenditure | -$4.5M | -$1.6M | -$10.9M | -$49.9M |
| Free cash flow | -$79.5M | -$46.8M | -$67.2M | -$120.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |